These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37927173)

  • 1. Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
    Camilleri M; Carlson P; Dilmaghani S
    Obesity (Silver Spring); 2024 Feb; 32(2):232-233. PubMed ID: 37927173
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
    Quast DR; Schenker N; Menge BA; Nauck MA; Kapitza C; Meier JJ
    Diabetes Care; 2020 Sep; 43(9):2137-2145. PubMed ID: 32647054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
    Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M
    Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
    Haluzík M; Trachta P; Mráz M
    Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.
    Rayner CK; Jones KL; Wu T; Horowitz M
    Diabetes Obes Metab; 2017 Mar; 19(3):309-312. PubMed ID: 27862814
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefits of GLP-1 drugs beyond obesity.
    Drucker DJ
    Science; 2024 Jul; 385(6706):258-260. PubMed ID: 39024455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
    Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
    Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A; Knop FK; Vilsbøll T
    Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas.
    McIntyre RS
    Expert Opin Drug Saf; 2024 May; 23(5):539-542. PubMed ID: 38520274
    [No Abstract]   [Full Text] [Related]  

  • 16. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
    Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Large Study of GLP-1 Receptor Agonists During Pregnancy.
    Harris E
    JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170560
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
    Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
    Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.